Insmed Incorporated (NASDAQ:INSM) COO Sells $3,378,264.75 in Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 42,975 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $78.61, for a total value of $3,378,264.75. Following the completion of the transaction, the chief operating officer now owns 146,082 shares of the company’s stock, valued at $11,483,506.02. This trade represents a 22.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Roger Adsett also recently made the following trade(s):

• On Thursday, February 6th, Roger Adsett sold 45,605 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total value of $3,689,444.50.
• On Tuesday, January 14th, Roger Adsett sold 1,457 shares of Insmed stock. The stock was sold at an average price of $68.72, for a total value of $100,125.04.
• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The shares were sold at an average price of $63.68, for a total transaction of $312,159.36.
• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The stock was sold at an average price of $65.95, for a total transaction of $161,181.80.

Insmed Stock Down 0.4 %

NASDAQ:INSM traded down $0.29 on Wednesday, reaching $79.60. The stock had a trading volume of 1,389,754 shares, compared to its average volume of 1,907,916. The company has a 50-day moving average of $73.15 and a 200 day moving average of $73.16. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a market cap of $14.24 billion, a P/E ratio of -14.34 and a beta of 1.11. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $82.04.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on INSM shares. JPMorgan Chase & Co. increased their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Guggenheim lifted their target price on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a report on Friday, February 7th. Morgan Stanley boosted their price target on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Stifel Nicolaus raised their price objective on Insmed from $88.00 to $97.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Truist Financial reiterated a “buy” rating and set a $105.00 target price (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, Insmed has a consensus rating of “Moderate Buy” and an average target price of $85.60.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Insmed by 6.3% in the 4th quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock valued at $1,257,838,000 after purchasing an additional 1,075,796 shares in the last quarter. Geode Capital Management LLC raised its holdings in Insmed by 7.2% in the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock valued at $282,243,000 after acquiring an additional 273,759 shares in the last quarter. Artisan Partners Limited Partnership boosted its stake in Insmed by 8.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,126,339 shares of the biopharmaceutical company’s stock valued at $215,842,000 after acquiring an additional 242,242 shares during the last quarter. William Blair Investment Management LLC grew its holdings in Insmed by 0.5% during the 4th quarter. William Blair Investment Management LLC now owns 2,433,443 shares of the biopharmaceutical company’s stock worth $168,005,000 after acquiring an additional 12,535 shares in the last quarter. Finally, Pictet Asset Management Holding SA increased its position in shares of Insmed by 5.2% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,959,718 shares of the biopharmaceutical company’s stock worth $135,299,000 after purchasing an additional 96,377 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.